Search - tctmd.com

Displaying 1 - 20 of 108

Sort: Relevancy | Date

News Daily News

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

Shelley Wood

April 14, 2023

News Daily News

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Shelley Wood

December 22, 2021

News

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Yael L. Maxwell

July 13, 2021

News Conference News EuroPCR 2021

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

Todd Neale

May 18, 2021

News Daily News

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

Yael L. Maxwell

April 05, 2021

News Conference News ACC 2019

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

Michael O'Riordan

March 18, 2019

Presentation JIM 2019

GP IIb/IIIa inhibitors are still the best option

Presenter: Alberto Menozzi

February 15, 2019

News Conference News AHA 2018

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

Shelley Wood

November 11, 2018

News Daily News

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Yael L. Maxwell

October 03, 2017

News Conference News ESC 2017

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

Shelley Wood

September 01, 2017

Presentation iASSESS 2017

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Presenter: Sripal Bangalore

August 30, 2017

News Conference News ESC 2017

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Shelley Wood

August 27, 2017

News Daily News

Viper Peptides Explored Anew as Antiplatelet Drugs

Yael L. Maxwell

June 08, 2017

News Daily News

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

Todd Neale

May 22, 2017

News Daily News

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Yael L. Maxwell

December 06, 2016

News Daily News

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

November 11, 2016

Presentation TCT 2016

Is There a Current Role for Intracoronary Lytics or GP IIb/IIIa Inhibitors During Primary PCI?

Presenter: Deepak L. Bhatt, Stefan K. James, C. Michael Gibson

October 31, 2016

News Conference News TCT 2016

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Yael L. Maxwell

October 31, 2016

Presentation TCT 2016

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients With ACS and PCI

Presenter: Frederick Feit, Sripal Bangalore

October 30, 2016

Presentation TCT 2016

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Presenter: A. Michael Lincoff, Franz-Josef Neumann, John A. Bittl

October 30, 2016

Advertisement

A Bivalirudin Rebuttal: ‘Some Issues’ to Discuss With BRIGHT-4

Still No Edge for Bivalirudin in VALIDATE-SWEDEHEART’s STEMI Patients

Tastes Like Ticagrelor: Mouth-Dissolving Pills Match Standard Ones in ACS

Subcutaneous GP IIb/IIIa Inhibitor in STEMI Is Fast, Potent in Early Study

New Antithrombotic Revacept Fails to Reduce Myocardial Injury in PCI

SAFARI Surprise: No Survival or Bleeding Advantage With Radial Over Femoral Access in STEMI

GP IIb/IIIa inhibitors are still the best option

T-Time: Alteplase Infusion No Help for Failed Reperfusion in STEMI PCI

Bleeding and Ischemic Events Fluctuate Out to 1 Year Post-STEMI: HORIZONS-AMI

Fentanyl, Ubiquitous in US Cath Labs, Blunts Antiplatelet Drugs in PCI

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients with ACS and in those Undergoing PCI

Latest Bivalirudin, Heparin Face-off in MI Cements Winner in Routine Practice: VALIDATE-SWEDEHEART

Viper Peptides Explored Anew as Antiplatelet Drugs

Large US Study Suggests Little Difference Between Bivalirudin and Heparin for Transradial Primary PCI

With No RCTs, Propensity-Score Matched Analysis Informs Choice Between Cangrelor and GPIs in the Cath Lab

Registry Data Show Rise and Fall of Bivalirudin vs Heparin for Primary PCI

Is There a Current Role for Intracoronary Lytics or GP IIb/IIIa Inhibitors During Primary PCI?

Opinions Still Mixed on Bivalirudin vs Heparin for Primary PCI

Antithrombin Therapy and GP IIb/IIIa Inhibitors in Patients With ACS and PCI

Do the Benefits of Bivalirudin Translate to Radial Intervention? Evidence From Randomized Trials

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content